Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 6
2018 5
2019 16
2020 24
2021 40
2022 30
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31151926

105 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
Bersanelli M, Buti S, Cortellini A, Bandini M, Banna GL, Pederzoli F, Farè E, Raggi D, Giannatempo P, De Giorgi U, Basso U, Losanno T, Santini D, Mucciarini C, Tucci M, Tambaro R, Farnesi A, Caffo O, Veccia A, Naglieri E, Briganti A, Procopio G, Pignata S, Necchi A. Bersanelli M, et al. Clin Med Insights Oncol. 2021 Jul 8;15:11795549211021667. doi: 10.1177/11795549211021667. eCollection 2021. Clin Med Insights Oncol. 2021. PMID: 34290538 Free PMC article.
First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Soria F, Teoh JYC, Egawa S, Powles T, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Mori K, et al. Eur J Cancer. 2021 Jul;151:35-48. doi: 10.1016/j.ejca.2021.03.049. Epub 2021 May 4. Eur J Cancer. 2021. PMID: 33962359 Free article.
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.
Erlmeier F, Klümper N, Landgraf L, Strissel PL, Strick R, Sikic D, Taubert H, Wach S, Geppert CI, Bahlinger V, Breyer J, Ritter M, Bolenz C, Roghmann F, Erben P, Schwamborn K, Wirtz RM, Horn T, Wullich B, Hölzel M, Hartmann A, Gschwend JE, Weichert W, Eckstein M. Erlmeier F, et al. Eur Urol. 2023 Feb;83(2):133-142. doi: 10.1016/j.eururo.2022.10.020. Epub 2022 Nov 10. Eur Urol. 2023. PMID: 36372626 Free article.
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT, Liu Y, Shabto JM, Martini DJ, Ravindranathan D, Hitron EE, Russler GA, Caulfield S, Yantorni LB, Joshi SS, Kissick H, Ogan K, Harris WB, Carthon BC, Kucuk O, Master VA, Bilen MA. Brown JT, et al. Oncologist. 2021 May;26(5):397-405. doi: 10.1002/onco.13727. Epub 2021 Mar 18. Oncologist. 2021. PMID: 33634507 Free PMC article.
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P, Ravaud A, Durán I, Szabados B, Castellano D, Giannatempo P, Loriot Y, Carles J, Anguera Palacios G, Lefort F, Raggi D, Gross Goupil M, Powles T, Van der Heijden MS. Gómez de Liaño Lista A, et al. Eur Urol. 2020 Feb;77(2):269-276. doi: 10.1016/j.eururo.2019.10.004. Epub 2019 Nov 5. Eur Urol. 2020. PMID: 31699525
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Meynard L, Dinart D, Delaunay B, Fléchon A, Saldana C, Lefort F, Gravis G, Thiery-Vuillemin A, Cancel M, Coquan E, Ladoire S, Maillet D, Rolland F, Boughalem E, Martin S, Laramas M, Crouzet L, Abbar B, Falkowski S, Pouessel D, Roubaud G. Meynard L, et al. Eur J Cancer. 2022 Nov;175:43-53. doi: 10.1016/j.ejca.2022.08.014. Epub 2022 Sep 8. Eur J Cancer. 2022. PMID: 36088671
First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis.
Lin CT, Su PJ, Huang SY, Wu CC, Wang HJ, Cheng YT, Luo HL, Chen CH, Liu TT, Huang CC, Su YL. Lin CT, et al. J Immunother. 2022 Nov-Dec 01;45(9):407-414. doi: 10.1097/CJI.0000000000000441. Epub 2022 Sep 20. J Immunother. 2022. PMID: 36121316 Free PMC article.
105 results